For people who struggle with persistent allergies, finding lasting relief can feel like a distant goal. Allergy immunotherapy offers a treatment option that gradually trains the immune system to become less sensitive to specific allergens. However, unlike medications that provide short-term symptom relief, immunotherapy requires patience and consistency.
Treatment typically takes three to five years, and the improvements you experience may change as you progress. Understanding the timeline can help you set realistic expectations and stay committed to your treatment plan.
The Early Stages: Building Allergen Tolerance
The first several months of immunotherapy focus on helping your body adjust to the allergens triggering your symptoms. During this initial phase, your specialist gradually increases your exposure to the allergen until you reach an effective maintenance dose.
Depending on your treatment plan, you may receive allergy shots at our office or use prescribed allergy drops at home. Your specialist will explain how to administer the drops safely and monitor your progress.
As your exposure increases, you may experience temporary reactions, such as sneezing, nasal congestion, itching or localized swelling. Mild reactions are often manageable, but more serious reactions, though rare, can occur. Seek emergency medical attention if you experience signs of anaphylaxis, including difficulty breathing, a drop in blood pressure, a weak pulse or swelling of the throat.
You may begin noticing small improvements within the first year. Some people using allergy drops experience relief within three to four months, while those receiving allergy shots may need six to 12 months to notice meaningful changes. Individual results vary based on the allergens involved, treatment method and consistency.
Years Two Through Five: Working Toward Lasting Relief
As treatment continues, many patients begin experiencing more substantial improvements. Allergy symptoms may become less frequent or severe, and you may find yourself relying less on symptom-relieving medications. However, progress is different for everyone, and some people respond more favorably than others.
Research supports the importance of sticking with treatment. A 2023 analysis of the REACT study found that patients who consistently followed their immunotherapy plans experienced greater reductions in allergic rhinitis symptoms than those who were less consistent. A 2025 study involving children and adolescents also found improvements in allergy and asthma symptoms, along with reduced medication use.
Your specialist will monitor your response throughout treatment and make adjustments when necessary. Even when symptoms improve, completing the recommended course is important for achieving the best possible long-term results.
Allergy immunotherapy requires a significant investment of time, but the possibility of enjoying everyday activities with fewer allergy symptoms can make that commitment worthwhile. Contact Eastern Oklahoma Ear Nose and Throat – Yale Office to schedule a consultation and learn whether immunotherapy could help you breathe easier and enjoy greater comfort throughout the year.
Sources
Johns Hopkins Medicine. (2024, July 13). Could allergy drops be the key to allergy relief? Johns Hopkins Medicine. https://www.hopkinsmedicine.org/health/conditions-and-diseases/seasonal-allergies/could-allergy-drops-be-the-key-to-allergy-relief
Cleveland Clinic medical professional. (2023). Allergy shots. Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/25194-allergy-shots
Contoli, M., Porsbjerg, C., Buchs, S., et al. (2023). Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study. Journal of Allergy and Clinical Immunology, 152, 445–452.e4.
Woehlk, C., Stranzl, T., Contoli, M., Freemantle, N., Slaettanes, A. K., Larsen, J. R., Porsbjerg, C., & Fritzsching, B. (2025). Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma. Allergy, 80(12), 3331–3341. https://doi.org/10.1111/all.70085